SCHEMBL14629683

SCHEMBL14629683

C=CNc1ccc(C#N)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 2/20 0.47
CA1 P00915 1/20 0.47
KDM4E B2RXH2 3/20 0.45
LMNA P02545 3/20 0.45
ALDH1A1 P00352 2/20 0.45
GAA P10253 1/20 0.45
CYP1B1 Q16678 1/20 0.45
CYP2A6 P11509 2/20 0.44
CA12 O43570 1/20 0.44
CA3 P07451 1/20 0.44
CA6 P23280 1/20 0.44
CA9 Q16790 1/20 0.44
CA14 Q9ULX7 1/20 0.44
IDO1 P14902 1/20 0.44
MMP2 P08253 1/20 0.44
HTT P42858 2/20 0.43
HPGD P15428 1/20 0.43
TSHR P16473 2/20 0.42
MAPT P10636 2/20 0.42
NLRP3 Q96P20 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31153234 0.84 ALDH1A1 (0.35) LMNAALDH1A1
SCHEMBL183353 0.78 ALDH1A1 (0.52) CA2CA1KDM4ELMNAALDH1A1
SCHEMBL6308662 0.78 CA2 (0.50) CA2CA1KDM4ELMNAALDH1A1
SCHEMBL360148 0.77 CA2 (0.48) CA2CA1KDM4ELMNAALDH1A1
SCHEMBL11300462 0.76 CA1 (0.50) CA2CA1KDM4ELMNAALDH1A1
SCHEMBL395539 0.76 CA2 (0.52) CA2CA1KDM4ELMNAALDH1A1
SCHEMBL22359689 0.75 KDM4E (0.47) CA2CA1KDM4ELMNAALDH1A1
SCHEMBL2503454 0.74 CA2 (0.69) CA2CA1ALDH1A1CYP2A6CA12
SCHEMBL45942 0.74 CA2 (0.69) CA2CA1ALDH1A1CYP2A6CA12
Water SCHEMBL28189314 0.74 CA2 (0.69) CA2CA1ALDH1A1CYP2A6CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070021483-A1 Amidine derivatives for treating amyloidosis NEUROCHEM (INTERNATIONAL) LIMITED (CH) 2007-01-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070021483-A1 Amidine derivatives for treating amyloidosis APP, IAPP, GRN CA2 3158/4885CA1 2928/4885KDM4E 3881/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.